Cargando…
Pharmacological Aspects of Vipera xantina palestinae Venom
In Israel, Vipera xantina palestinae (V.x.p.) is the most common venomous snake, accounting for several hundred cases of envenomation in humans and domestic animals every year, with a mortality rate of 0.5 to 2%. In this review we will briefly address the research developments relevant to our presen...
Autores principales: | Momic, Tatjana, Arlinghaus, Franziska T., Arien-Zakay, Hadar, Katzhendler, Jeoshua, Eble, Johannes A., Marcinkiewicz, Cezary, Lazarovici, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237004/ https://www.ncbi.nlm.nih.gov/pubmed/22174978 http://dx.doi.org/10.3390/toxins3111420 |
Ejemplares similares
-
Vixapatin (VP12), a C-Type Lectin-Protein from Vipera xantina palestinae Venom: Characterization as a Novel Anti-angiogenic Compound
por: Momic, Tatjana, et al.
Publicado: (2012) -
Vipegitide: a folded peptidomimetic partial antagonist of α2β1 integrin with antiplatelet aggregation activity
por: Momic, Tatjana, et al.
Publicado: (2015) -
Effect of Dimeric Disintegrins Isolated from Vipera lebetina obtusa Venom on Glioblastoma Cellular Responses
por: Galicka, Anna, et al.
Publicado: (2023) -
Human Umbilical Cord Blood Stem Cells: Rational for Use as a Neuroprotectant in Ischemic Brain Disease
por: Arien-Zakay, Hadar, et al.
Publicado: (2010) -
From Snake Venom’s Disintegrins and C-Type Lectins to Anti-Platelet Drugs
por: Lazarovici, Philip, et al.
Publicado: (2019)